Early Phase I Study of Autologous T Cells (EX02 CAR-T) for Unresectable Pancreatic/Bile Duct Cancer
Status:
Not yet recruiting
Trial end date:
2027-12-31
Target enrollment:
Participant gender:
Summary
This is a early Phase 1 open-label study to explore the safety and possible efficacy of EX02
CAR T cell therapy in the treatment of patients with unresectable and/or metastatic
pancreatic/bile duct cancer.
Each participant will undergo leukapheresis after enrolment, receive treatment of the
conditioning chemotherapy of cyclophosphamide and fludarabine, and an intra-tumoral injection
or intraperitoneal infusion of Ex02 CAR T cells, probably followed by an intravenous infusion
of EX02 CAR T cells.
Each participant will proceed through the following study procedures:
- Screening
- Enrollment/Leukapheresis
- Conditioning chemotherapy
- CAR T treatment
- Post-treatment assessment
- Long-term follow-up